Invesco Biotechnology & Genome ETF PBE

Morningstar Medalist Rating

Morningstar’s Analysis PBE

Will PBE outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Invesco Biotechnology & Genome ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PBE

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings50.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Regeneron Pharmaceuticals Inc

5.8825M
Healthcare

Biogen Inc

5.8725M
Healthcare

Gilead Sciences Inc

5.8025M
Healthcare

Royalty Pharma PLC Class A

5.6824M
Healthcare

Amgen Inc

5.3823M
Healthcare

Vertex Pharmaceuticals Inc

5.0121M
Healthcare

Illumina Inc

4.5319M
Healthcare

Natera Inc

4.4119M
Healthcare

Moderna Inc

3.8116M
Healthcare

Vericel Corp

3.7416M
Healthcare

Sponsor Center